tiprankstipranks
Advertisement
Advertisement

OCS Stock Latest News

Oculis price target lowered to $20 from $23 at JPMorgan
The FlyOculis price target lowered to $20 from $23 at JPMorgan
7d ago
OCS
Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics
PremiumCompany Announcements
Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics
13d ago
6K
OCS
Oculis price target lowered to $32 from $35 at BofA
PremiumThe Fly
Oculis price target lowered to $32 from $35 at BofA
13d ago
OCS
Oculis to acquire development, commercial rights to Privosegtor from Accure
PremiumThe Fly
Oculis to acquire development, commercial rights to Privosegtor from Accure
14d ago
OCS
Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing
PremiumCompany Announcements
Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing
17d ago
6K
OCS
Oculis reports Q2 EPS (16c), consensus (38c)
PremiumThe FlyOculis reports Q2 EPS (16c), consensus (38c)
17d ago
OCS
Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating
Premium
Ratings
Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating
18d ago
OCS
Oculis gets FDA pre-IND feedback regarding Privosegtor clinical development plan
Premium
The Fly
Oculis gets FDA pre-IND feedback regarding Privosegtor clinical development plan
21d ago
OCS
Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch
PremiumCompany Announcements
Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch
2M ago
OCS
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
PremiumCompany Announcements
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
2M ago
6K
OCS
Oculis price target lowered to $23 from $42 at JPMorgan
PremiumThe Fly
Oculis price target lowered to $23 from $42 at JPMorgan
3M ago
OCS
Oculis price target lowered to $38 from $49 at Baird
PremiumThe Fly
Oculis price target lowered to $38 from $49 at Baird
3M ago
OCS
Oculis price target lowered to $38 from $49 at Baird
PremiumThe FlyOculis price target lowered to $38 from $49 at Baird
3M ago
OCS
Video: Nvidia rallies after taking wraps off new PC processor
Premium
The Fly
Video: Nvidia rallies after taking wraps off new PC processor
3M ago
AMD
OCS
Oculis price target lowered to $35 from $44 at BofA
Premium
The Fly
Oculis price target lowered to $35 from $44 at BofA
3M ago
OCS
Oculis price target lowered to $38 from $46 at Needham
PremiumThe Fly
Oculis price target lowered to $38 from $46 at Needham
3M ago
OCS
Oculis price target lowered to $45 from $75 at Guggenheim
PremiumThe Fly
Oculis price target lowered to $45 from $75 at Guggenheim
3M ago
OCS
Oculis price target lowered to $26 from $47 at H.C. Wainwright
PremiumThe Fly
Oculis price target lowered to $26 from $47 at H.C. Wainwright
3M ago
OCS
Oculis price target lowered to $40 from $50 at Stifel
PremiumThe Fly
Oculis price target lowered to $40 from $50 at Stifel
3M ago
OCS
Oculis Maintained at Buy as Analyst Lowers Price Target to $45, Refocuses on Optic Neuritis Opportunity
PremiumRatingsOculis Maintained at Buy as Analyst Lowers Price Target to $45, Refocuses on Optic Neuritis Opportunity
3M ago
OCS
Analyst Maintains Buy on Oculis, Sees Upside Driven by Optic Neuropathy and Dry Eye Pipelines Despite OCS-01 Phase 3 Setback
Premium
Ratings
Analyst Maintains Buy on Oculis, Sees Upside Driven by Optic Neuropathy and Dry Eye Pipelines Despite OCS-01 Phase 3 Setback
3M ago
OCS
Oculis Holding AG trading resumes
Premium
The Fly
Oculis Holding AG trading resumes
3M ago
OCS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >